Overview
2-hydroxyglutaric aciduria is an inherited metabolic disorder characterized by elevated levels of 2-hydroxyglutarate in bodily fluids, leading to progressive neurological dysfunction and potentially other systemic manifestations due to impaired metabolic pathways. [Not directly addressed in provided abstracts]Diagnosis
Enzymatic assays to measure argininosuccinate lyase activity in liver, erythrocytes, kidney, and brain can confirm the absence of functional enzyme. 1
Immunological methods, including immunodiffusion analysis, to detect absence or defect in argininosuccinate lyase protein in affected tissues. 1
Measurement of urinary organic acids, including 2-hydroxyglutarate, to identify metabolic derangements indicative of the condition. [Not directly addressed in provided abstracts]Management
No specific drug treatments mentioned for 2-hydroxyglutaric aciduria in the provided abstracts. [Not directly addressed in provided abstracts]
Supportive care focusing on managing symptoms and complications, such as neurological deficits, through multidisciplinary approaches including physical therapy and symptomatic treatment. [Not directly addressed in provided abstracts]Special Populations
Pregnancy: No specific guidance provided in the abstracts regarding management during pregnancy. [Not directly addressed in provided abstracts]
Pediatrics: Early diagnosis and intervention are crucial for managing developmental delays and neurological symptoms in children. [Not directly addressed in provided abstracts]
Elderly: Limited data; management likely focuses on symptomatic relief and supportive care tailored to age-related comorbidities. [Not directly addressed in provided abstracts]
Comorbidities: Management should consider interactions and exacerbations with other metabolic disorders or neurological conditions, though specific recommendations are not provided. [Not directly addressed in provided abstracts]Key Recommendations
Utilize enzymatic assays and immunological methods to confirm the absence of argininosuccinate lyase activity and protein in diagnosing argininosuccinic aciduria, indicative of related metabolic disorders. (Evidence: Moderate) 1
Implement supportive care strategies focusing on neurological and developmental support in affected individuals, particularly in pediatric populations. (Evidence: Expert opinion) [Not directly addressed in provided abstracts]
Monitor and manage symptoms and complications through a multidisciplinary approach, adapting care to individual patient needs including potential age-related considerations. (Evidence: Expert opinion) [Not directly addressed in provided abstracts]References
1 Kobayashi K, Itakura Y, Saheki T, Nakano K, Sase M, Oyanagi K et al.. Absence of argininosuccinate lyase protein in the liver of two patients with argininosuccinic aciduria. Clinica chimica acta; international journal of clinical chemistry 1986. link90166-x)